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Lung cancer research has recently made signiﬁcant progress in understanding the molecu-
lar pathogenesis of lung cancer and in developing treatments for it. Such achievements are
directly utilized in clinical practice. Indeed, the echinoderm microtubule-associated protein-
like 4–anaplastic lymphoma kinase (ALK) fusion gene was ﬁrst described in non-small cell
lung cancer in 2007 , and a molecularly targeted drug against the fusion was approved in
2011. However, lung cancer with the ALK fusion constitutes only a small fraction of lung
cancers; therefore, efﬁcient patient selection is crucial for successful treatment using the
ALK inhibitor. Currently, RT-PCR, ﬂuorescent in situ hybridization (FISH), and immunohis-
tochemistry are commonly used to detect the ALK fusion. Although FISH is currently the
gold standard technique, there are no perfect methods for detecting these genetic alter-
ations. In this article, we discuss the advantages and disadvantages of each method and
the possible criteria for selecting patients who are more likely to have theALK fusion. If we
can successfully screen patients, then ALK inhibitor treatment will be the best example
of personalized therapy in terms of selecting patients with an uncommon genotype from
a larger group with the same tumor phenotype. In other words, the personalized therapy
may offer a new challenge for current clinical oncology.
Keywords:anaplasticlargecelllymphomakinase,non-smallcelllungcancer,immunohistochemistry,RT-PCR,FISH,
screening, molecular targeted drugs
INTRODUCTION
Lung cancer research has recently made signiﬁcant progress in
understanding the molecular pathogenesis of lung cancer and in
developing treatments for it. For example, epidermal growth fac-
tor receptor (EGFR) tyrosine kinase inhibitors (EGFR–TKIs) have
been developed, and a subset of lung cancer patients have shown
dramatic therapeutic responses to these treatments. Subsequently,
thissuperiorresponsewasrevealedtobeassociatedwiththeEGFR
mutation, which was identiﬁed in 2005 (Lynch et al., 2004; Paez
et al., 2004). Currently, EGFR–TKIs are the ﬁrst-line treatments
for patients with advanced disease when the tumor is positive for
the EGFR mutation. More recently, a similarly marked response
to an anaplastic lymphoma kinase (ALK) inhibitor was demon-
strated in patients with ALK fusion-bearing lung cancer (Kwak
et al.,2010).
The echinoderm microtubule-associated protein-like 4
(EML4)–ALK fusion in non-small cell lung cancer (NSCLC) was
ﬁrst described in 2007 (Rikova et al.,2007; Soda et al.,2007). This
fusion results from a small inversion within chromosome 2p that
leads to the expression of a chimeric tyrosine kinase in which the
N-terminal half of the EML4 is fused to the intracellular ALK
kinase domain. The strong in vitro (Soda et al., 2007) and in vivo
(Soda et al., 2008) oncogenic activity of the fusion protein has
been demonstrated,and the inhibition of the fused molecule with
ALK inhibitors leads to a marked deterioration of the tumor cells
in vitro, supporting that ALK fusion is a driver mutation of lung
cancer. A dramatic response to the ALK inhibitor similar to that
of the EGFR–TKIs was expected and was observed. However, the
prevalence of the fusion is low, ranging from 2 to 4% in the lit-
erature (Inamura et al., 2008; Koivunen et al., 2008; Perner et al.,
2008; Shinmura et al., 2008; Takahashi et al., 2010) and in our
consecutive series (Table 1). Even when the patients are selected
for their predictive clinical characteristics,such as a lower median
age and not having a history of smoking, it is difﬁcult to identify
the subsets of ALK-positive tumors. Therefore,efﬁcient screening
for the ALK fusion gene is a crucial issue in clinical practice.
Approximately one-third of lung cancer patients are diagnosed
with localized disease that can be treated by surgical resection
(Molina et al., 2006); however, nearly 30–35% will relapse after
the initial surgery, even following a diagnosis at the earliest stage.
For these patients, the surgically resected tissue may serve as
an important sample for further molecular study because the
recurrent tumor is often impossible to access without invasive
procedures. In contrast, the other two-thirds of patients present
with advanced, inoperable disease, and therefore a biopsy or a
cytology specimen may be the only available tissue. Therefore,
the methods used for detecting the ALK fusion should be applic-
able to these small tissue and cytology specimens. Currently,
there are three methods for ALK testing: RT-PCR, ﬂuorescent
in situ hybridization (FISH) and immunohistochemistry. Because
there is no perfect method, we need to know the applicable
range of the samples and the sensitivity, speciﬁcity and limita-
tions of the individual methods. Before explaining the details
of these methods, we will consider whether the targeted patient
population can be identiﬁed based on their clinicopathological
features.
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Table 1 | Clinicopathological characteristics ofALK-positive lung cancers.
Characteristics All patients (n =811) Genotype
ALK (n =31) EGFR (n =324) KRAS (n =62) Null (n =331)
AGE,YEAR
Median 63 561 65 64 65
Range 22–89 35–76 31–89 41–80 22–83
SEX
Female 362 212 198 15 111
Male 449 10 126 47 210
SMOKING STATUS
Never smoked 359 213 211 14 99
Smoker 452 10 112 48 222
HISTOLOGY
Adenocarcinoma 713 30 322 56 231
Squamous cell 52 1 0 2 48
Adenosquamous 8 0 1 1 7
Other 38 0 0 3 35
PATHOLOGICAL STAGE
I 492 18 225 40 168
II 137 4 34 10 72
III 150 8 54 9 70
IV 32 1 10 3 11
1Statistically signiﬁcant by the independent sample two-tailed t-test (p<0.002).
2Statistically signiﬁcant difference in sex between the ALK-positive and negative tumors (p=0.001).
3Statistically signiﬁcant difference in smoking status between the ALK-positive and negative tumors (p=0.001).
CONCENTRATION OF THE PATIENTS WITH ALK-POSITIVE
LUNG CANCER
CLINICOPATHOLOGICAL FEATURES
Because ALK-positive lung cancer constitutes less than 5% of
all lung cancers (Sasaki et al., 2010), it is critically important to
select those patients who are more likely to have the ALK muta-
tion. We initially attempted to select the patient population based
on their clinicopathological features. As shown in Table 1, the
patientswithALK-positivecancerswerecharacteristicallyyounger
(a median age of 56 vs. 63),more frequently female,and more fre-
quently non-smokers. In addition, the ALK fusion has a mutually
exclusive relationship with the EGFR, KRAS, and HER2 muta-
tions. Therefore, we attempted to select the ALK-positive lung
cancer patients based on these clinicopathological features. The
prevalenceoftheALKtranslocationinthefemalepatientsyounger
than 63 without the EGFR, KRAS, HER2, or p53 mutations was
25% (Figure 1). However, four patients were not included in this
subset (Mitsudomi et al., 2010). The selection of patients using
clinicopathological features alone was able to increase the preva-
lence of the ALK mutation in our sample but was not able to
identify all of the patients with it.
MORPHOLOGICAL FEATURES
An alternative method of selection uses the morphological fea-
tures of the tumors. Table 2 contains several morphological fea-
turesknowntobecharacteristicofALK-positiveadenocarcinomas
(Figure 2). These characteristics have been identiﬁed in studies
comparingALK-positiveandALK-negativelungcancers(Inamura
Table 2 | Morphological characteristics of theALK-positive tumors.
Growth pattern
Acinar
Cribriform
Solid
Differentiation/grade
Poorly differentiated
Cellular features
Signet ring cell carcinoma
Cytoplasmic features
Mucin production
et al., 2008; Rodig et al., 2009; Takeuchi et al., 2009;Yoshida et al.,
2011),mostly using surgical specimens.Among these features,the
presence of signet ring cells has the highest predictive value for
ALK-positivelungcancer.AccordingtoRodigetal.(2009)theALK
fusion was detected in 12 of the 26 tumors that they identiﬁed as
havinggreaterthan10%signetcellsbyarea,althoughsuchtumors
constituted only 8% of total lung adenocarcinomas. By contrast,
theothermorphologicalcharacteristicsweremorefrequentlyseen
inALK-negativetumors.Thesolid-subtypewassigniﬁcantlymore
frequent in the ALK-positive cancers; however, the ALK-positive
rate was 8% among the solid-subtype adenocarcinomas.
In practice, candidate patients for ALK inhibitor treatments
typicallyhaveadvancedcancer,andtheirbiopsyspecimensand/or
cytology are the major source of samples. Therefore, predicting
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FIGURE 1 | Concentration of EML4–ALK translocation using
clinicopathologic features (n =345). Numbers in black squares indicate
number of patients with ALK translocation. Incidence of ALK translocation
became 25% when patients were conﬁned to those without EGFR, KRAS,
HER2, p53 mutations and to female patients younger than 63. However, four
patients were not included in this subset (Mitsudomi et al., 2010).
FIGURE 2 | Morphological characteristics ofALK-positive lung cancer.The
cribriform pattern (A) is composed of fused acini or glands.The solid-growth
pattern consists of tumor cell nests without structural architecture (B). Solid
adenocarcinoma cells with the ALK fusion often have vesicular nuclei with
convoluted contours and deep grooves.This subtype may be misdiagnosed as
squamous cell carcinoma or mucoepidermoid carcinoma in some cases.
Signet ring cell carcinoma (C) is also characteristic of ALK-positive lung
cancer. Rodig et al. (2009) found that 71% of the adenocarcinomas that
consisted of more than 10% signet ring cells harbored the ALK fusion. One
cellular characteristic of ALK-positive lung cancer is mucin production. In
extreme cases, the alveolar space is ﬁlled with mucin (D), although the
lumens of the neoplastic glands seldom open to the alveolar spaces.
Although the majority of mucinous tumors are negative forTTF-1, the
ALK-positive tumors (i.e., the signet ring cell carcinomas) are an exception.
these patients’ ALK fusion status based solely on morphological
features is notably difﬁcult.
THREE KEY METHODS OF DETECTING ALK FUSION
Currently, the methods of RT-PCR, FISH, and immunohisto-
chemistry have been used to detect the ALK fusion gene. Because
each method inevitably has both advantages and disadvantages
(Table 3), we should be aware of their characteristics before
applying them to clinical samples.
RT-PCR
RT-PCRistechnicallyeasyandrapid.Thechromosomalinversion
thatcharacterizestheALKfusionmakesthesequenceunique,and
the PCR primer only hybridizes with the fusion chimeric tran-
script. This unique primer is responsible for the high sensitivity
of this method. Soda et al. (2007) detected fusion mRNA in spu-
tum that contained as few as 10 EML4–ALK-expressing BA/F3
cells. This method is used only for known fusion partners, how-
ever,and all 11 of the reported variants require skillful application
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of the technique because of the long PCR products. In addition,
high-quality RNA is difﬁcult to obtain in clinical practice. We
found that 4 of the 361 tumors we screened had inconsistent
RT-PCR and immunohistochemical results. Three of the tumors
revealed both new and known variants of the EML4–ALK fusion
transcript with 5 -RACE. Therefore, this method is difﬁcult to
implement in a routine clinical diagnostic laboratory. However,
RT-PCR is one of the few methods that provide direct evidence
of the chromosomal translocation. A demonstration of chimeric
transcription is the best direct evidence of the translocation;if the
Table 3 |Advantages and disadvantages ofALK detection methods.
Pros Cons
RT-PCR A potentially rapid diagnostic method Difﬁcult to obtain high-quality of RNA
Very sensitive Not applicable for unknown partners
More accurate Difﬁcult to conﬁrm the presence of tumor cells
Difﬁcult to apply to archival tissues
FISH Applicable for any partners Expensive
Screening method in clinical trials Relative long turnaround time
Established in many labs Less sensitive
Applicable to archival tissues
IHC Applicable for any partners Indirect demonstration of the fusion gene
Rapid turnaround time Occasional false negative results
Established in many labs High dependence on antibody clones and detection methods
Applicable to archival tissues
Cheap
FIGURE 3 | Fluorescent in situ hybridization method forALK fusion
detection.The probes, which are labeled with different ﬂuorescences, are
designed at telomeric and centromeric sides between break point (A).
Representative FISH images of ALK-negative (B) and positive tumors (C)
are displayed. When ALK is translocated, the signals are changed from
merged yellow to single red and green.The current criteria of the gene
rearrangement and positive ALK FISH are as follows. Cells are considered
rearrangement positive when: (i) At least one set of orange and green
signals are two or more signal diameters apart. (ii)There is a single orange
signal without a corresponding green signal in addition to fused and/or
broken apart signals.The tumor is considered positive ALK test when: (i) A
sample is considered negative if <5 cells out of 50 (<5/50 or <10%) are
positive. (ii) A sample is considered positive if >25 cells out of 50 (>25/50
or >50%) are positive. (iii) A sample is considered equivocal, if 5–25 cells
(10–50%) are positive. If the sample is equivocal, a second reader should
evaluate the slide.
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results are negative, however, it is clinically difﬁcult to determine
whether the tumor is truly negative for theALK fusion or whether
it was not detected due to impaired RNA integrity or technical
errors.
FLUORESCENT IN SITU HYBRIDIZATION
Fluorescent in situ hybridization is currently the gold standard
method used in clinical trials to detect theALK fusion gene,and it
was the ﬁrst FDA-approved method for detecting the ALK fusion
(Kwak et al., 2010). The FISH technique has been established in
several labs to perform the HER2 test for breast cancer. FISH has
the signiﬁcant advantage of allowing archival material to be used.
FISH also has disadvantages, however, including a relatively high
costandalongturnaroundtime.Theevaluationofpositivesignals
also requires considerable skill,especially when using biopsy sam-
ples. A break-apart FISH probe has been used to detect the ALK
fusion (Figure 3), and the probes are designed for the telomeric
and centromeric sides of the break points. Therefore, this design
is applicable in detecting any kind of fusion partner, and any
type of ALK gene rearrangement could theoretically be detected
using this technique. However,it is known that some tumors with
RT-PCR proven and ALK immunohistochemistry (IHC)-positive
ALK fusions show non-split signals under the current criteria
(Figure 4).
IMMUNOHISTOCHEMISTRY
In contrast, immunohistochemical analysis is technically easy
because it is integrated into routine pathological diagnosis. This
assay has the advantages of rapidity, allowing the use of archival
tissues,theabilitytodetectanypartnergenes,andsimplecompar-
isons of morphology. Although the immunohistochemical tech-
nique does not detect the ALK fusion gene itself, ALK is not
detectable in any normal tissues other than the brain (Iwahara
etal.,1997).Therefore,anALK-positivereactionisassociatedwith
dysregulated expression of the gene, due to the altered promoter
activity that is highly characteristic of an ALK inversion.
The early studies of ALK fusion immunohistochemistry
reported that not all fusion-positive tumors yielded a positive
immunohistochemistry result (Martelli et al., 2009). In contrast
to the ALK fusion in anaplastic large cell lymphoma, the mRNA
expression is lower in lung cancer; therefore, the false negative
results appear to be caused by lower sensitivity. In general, the
detection threshold is determined by the afﬁnity of the primary
antibodyandthesignalampliﬁcationsystem.Intermsof theanti-
body afﬁnity, Mino-Kenudson et al. (2010) compared two clones
of the anti-ALK antibody and found large differences in their
afﬁnities for lung cancer cells. Nevertheless, it has been reported
that highly sensitive immunohistochemistry is quite effective at
detecting the ALK fusion gene. Takeuchi et al. (2009) compared
the immunohistochemical results of combining three anti-ALK
antibodies and two detection systems and found that all of the
ALK-positive tumors could be detected by their highly sensi-
tive immunohistochemical system, regardless of the differences
betweentheclones.Thesetwokeyfactors,theantibodyclonesand
the detection system, are important for detecting the ALK fusion
byimmunohistochemistry(Mitsudomietal.,2011).Indeed,when
FIGURE 4 |A case with EML–ALK-positive adenosquamous cell
carcinoma, showing negative FISH.The tumor was a well-circumscribed
nodule (A), in which both components of adenocarcinoma (B) and squamous
cell carcinoma (C) were histologically identiﬁed.The chimeric transcript was
detected with RT-PCR products (D), in addition to positive ALK-IHC (E).
However, FISH results did not fulﬁll the positive criteria (F).
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we compared the results obtained using theALK1 antibody with a
conventional detection system to those obtained using the (high-
afﬁnity) 5A4 antibody with a highly sensitive detection system
(Envision FLEX+ system), we found that 3 of 12 ALK-positive
tumorswentundetectedbytheformermethod(Table 4;Figure5).
5A4 and D5F3 are known to be high-afﬁnity antibody clones.
Table 4 | Comparison between conventional (ALK1 and standardABC methods) and optimized IHCs (5A4 and Flex+ system) using tissue
microarray and biopsy specimens.
5A4 positive 5A4 negative
TISSUE MICROARRAY (n =361)
ALK1 positive 10 0
ALK1 negative 3 348
BIOPSY (n =43)
ALK1 positive 3 0
ALK1 negative 3 37
FIGURE 5 | Discordant results according to antibody clones and
detection system. A biopsy specimen only contains a small number of tumor
cells [H&E staining, (A)]. When ALK1 antibody and conventional detection
system was used, IHC showed negative results for tumor cells [(B),
arrowheads]. However, proper clone (clone 5A4) and highly sensitive
detection method (Envision FLEX+) made tumor cells show clearly positive
reactions (C). Gene rearrangement and chimeric transcript of EML4–ALK
fusion had been shown with FISH and RT-PCR in this specimen.
Table 5 | Comparison of IHC results according to the difference of antibody clones (5A4 and D5F3).
D5F3
5A4 Positive Negative Membranous only
Positive 121 09 4 3
Negative 12 343 264
1Chimeric transcripts of EML4–ALK were detected in all cases.
2The tumor was negative for chimeric transcript of EML4–ALK and FISH.
3The tumors were negative for chimeric transcript of EML4–ALK.
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FIGURE 6 |A case ofALK-IHC positive small cell lung cancer. A lung
nodule was biopsied from the 83-year-old female smoker. H&E section
(A) shows typical morphology of small cell lung cancer and
CD56/NCAM and synaptophysin were positive. Although it is little
reports of SCLC with ALK fusion, the tumor cells were positive for ALK
immunohistochemistry using clone 5A4 and Envision FLEX+ (B).N o
gene rearrangement and chimeric transcript of EML4–ALK have been
detected, respectively.
When a highly sensitive detection system was used, either clone
was able to detect all of the ALK-positive cancers, although
D5F3causedmembranousstaininginsomeALK-negativetumors
(Table 5).
Because IHC does not directly demonstrate ALK fusion, there
are certain pitfalls. Certain small cell lung cancers have positive
reactions (Figure 6) but do not have the ALK translocation. This
positivereactiondidnotappeartobeassociatedwithgeneampliﬁ-
cation,and the reason for the positive reaction was unknown. The
ALK protein may be expressed in association with the neuroecto-
dermal differentiation of small cell lung cancer, as it is expressed
in the normal brain (Iwahara et al.,1997). Another pitfall is a cer-
tain rate of false negative reactions in signet ring cells, even when
using a high-afﬁnity antibody with a highly sensitive detection
method. A large amount of cytoplasmic mucin can often push
the cytoplasm into the rim, and the thinned cytoplasm weakly
demonstrates a positive reaction in certain cases (Figure 7). For-
tunately, pure signet ring cell carcinoma is extremely uncommon
inlungcancer,andtheothertumorcomponentscanshowpositive
reactions,or a FISH analysis can be used instead.
ALK TESTING GUIDELINES BY THE JAPANESE LUNG CANCER
SOCIETY
TheALKinhibitorcrizotinibisexpectedtobeintroducedinJapan,
and we face the practical application of the methods described
above because this agent will be approved for patients with ALK
fusiondetectedusinganymethods.ThisisincontrastwithUSpol-
icy, where crizotinib has been approved for ALK-positive patients
only with an FDA-approved test. As noted, different precautions
are necessary for individual methods as well as the appropriate
FIGURE 7 |A pitfall of false negative immunohistochemistry in the
mucinous component of adenocarcinoma, including signet ring cell
carcinoma. Although the adenocarcinoma (A) was conﬁrmed to harbor
ALK fusion with both FISH and RT-PCR, immunohistochemistry using clone
D5F3 and Envision FLEX+ showed various intensity of positive reactions
(B). An upper part of the tumor cells (D) presented strong positivity, while
the lower part showing signet ring cell carcinoma morphology appeared to
be negative (C). Large amount of intracellular mucin pushes out cell
cytoplasm outward to the rim.This false negative reaction does not indicate
heterogeneity of ALK fusion, because split signals was demonstrated in
both components.
handling of the tissues. Under the circumstances, the Japanese
LungCancerSocietyissuedaguidelineforALKtesting(Figure8).
Theguidancementioneddetailedtheprosandconsofthesemeth-
ods, precautions for tissue handling, tissue application (biopsy,
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FIGURE 8 | Diagnostic algorithm forALK fusion from the Japanese
Lung Cancer Society.The standard procedure for formalin-ﬁxed parafﬁn
embedded specimens involves screening with immunohistochemistry and
conﬁrmation with FISH. Even when the ALK immunohistochemistry is
negative, FISH is recommended for the patients who are suspected of
harboring the ALK fusion based on clinical considerations (age lower than
40years, for example), and morphology (e.g., a mucinous cribriform
pattern, signet ring cells, andTTF-1 positivity in mucinous
adenocarcinomas). For pleural effusions and/or cytology samples, a
positive RT-PCR can conﬁrm the ALK fusion and directly facilitate crizotinib
treatment. However, a negative RT-PCR does not have any clinical
signiﬁcance, and further examinations are required. Because each method
has advantages and disadvantages, the use of more than one method to
detect ALK fusion is recommended.
cytology, and surgical specimens) and comparisons of the three
methods, including the different results of the various antibody
clones against ALK for immunohistochemistry. Although valida-
tion of this algorithm has recently begun in a large prospective
cohort, it is stressed that concurrent multiple methods should be
used to select ALK-positive patients.
CONCLUSION
ThelungcancerwithALKfusionconstitutesonlyafewpercentages
in overall lung cancer, thus the target proportion is very lim-
ited in comparison with the other molecular targeted treatments.
However, if we succeed to achieve successful screening of the
patients, the treatment with ALK inhibitor will be the most rep-
resentative personalized therapy in terms of selecting the patients
from those harboring the same category of tumors according to
the infrequent gene alteration. In other words, the achievement
may be a new challenge for the current clinical oncology.
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